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Abstract  
 
Background:  Racial and ethnic differences in the presentation and outcomes of patients 
waitlisted with acute liver failure (ALF) have not been explored. 
 
Methods: Adult patients waitlisted for liver transplantation (LT) from 2002-2016 with ALF 
were investigated using the United Network of Organ Sharing database.  Clinical 
characteristics and causative etiologies were compared between white, black, Hispanic, and 
Asian patients with ALF who were waitlisted Status-1.  A competing risk analysis was used 
to explore differences in LT and waitlist removal. Kaplan-Meier survival curves were used to 
explore differences in 1-year post transplant survival.  
 
Results:  There were 8,208 patients waitlisted with a primary diagnosis of ALF; 4,501 were 
waitlisted Status-1 (55.3% of whites, 64.4% of blacks, 51.6% of Hispanics, 40.7% of Asians, 
p<0.001).  Black patients had higher bilirubin, INR, and MELD at waitlisting than other 
groups. White patients were the most likely to have acetaminophen toxicity as a causative 
etiology, while black patients were the most likely to have autoimmune liver disease.  Black 
patients were significantly more likely to undergo LT than white patients (HR 1.20; 95% CI 
1.30-1.86).  There was no difference in waitlist removal because of death or clinical 
deterioration among racial/ethnic groups. One year post transplant survival was lowest in 
black patients (79.6% blacks vs 82.8% whites, 83.9% Hispanics, 89.3% Asians, p=0.02).  
 
Conclusions: Etiologies of ALF vary by race and ethnicity.  Black patients with ALF were 
more likely to be waitlisted Status-1 and undergo LT than white patients, but were sicker at 
presentation. One-year post transplant survival was lowest amongst black patients.   
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Introduction 
 
 Acute liver failure (ALF) is a rare but life threatening illness that results in hepatic 
dysfunction, coagulopathy, encephalopathy, complicated in 30% of cases by death 1,2.  While 
approximately 45% of patients with ALF will recover with supportive care, 25% will require 
liver transplantation (LT) 3.   
 Racial and ethnic disparities in treatment of chronic liver disease and its sequelae 
have been described, with ethnic and racial minorities being less likely to receive 
transhepatic portosystemic shunts, timely esophgogastrodudenoscopy for variceal 
hemorrhage, or direct acting antiretroviral agents for hepatitis C4-6. There were racial 
disparities in LT for chronic liver disease in the past that have improved with adoption the 
model for end stage liver disease score (MELD)7,8.  The ALF Study Group found no 
difference in mortality or LT between black and white patients with ALF; however the number 
of black patients was relatively small and the cohort begin enrolling in 1998, prior to the 
MELD era2.  Less is known about racial or ethnic differences in the access to LT in this 
group in the modern era. 
 The criteria for Status-1 waitlisting are strict and require a life expectancy of less than 
7 days without LT and fulminant liver failure without pre-existing liver disease, or hepatic 
artery thrombosis within 7 days of transplant, primary non-function of a previous hepatic 
allograft, or acute decompensated Wilsons Disease 9.  The decision to apply for Status-1 
waitlisting is based on the clinician’s judgement about a patients clinical course and 
likelihood of recovery without transplant.  In light of this, it is important that clinicians 
understand the clinical presentations and outcomes of a diverse group of patients with ALF 
in order to make informed decisions about the need for LT.  It is also important that we 
explore in racial and ethnic differences in access to transplant services.   The goal of this 
study was to explore differences in the presentations, causative etiologies, and outcomes 
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between racial and ethnic minorities waitlisted Status-1 with ALF for LT in the United States 
(U.S.). 
 
Methods 
 
Study Population 
 
A retrospective cohort study of adult (18 years and older) patients waitlisted for LT in 
the U.S. with a diagnosis of ALF between February 27, 2002 and December 31, 2016 was 
conducted.  The United Network of Organ Sharing (UNOS) maintains the Standard 
Transplant Analysis and Research (STAR) database which includes data on all candidates 
waitlisted for LT, including information regarding their diagnosis.  
To determine the number of patients with ALF who required Status-1 waitlisting all 
patients with ALF were first identified. ALF was defined by a primary diagnosis code of ALF 
or an unknown primary diagnosis code coupled with Status-1 waitlisting and a free text 
diagnosis code consistent with ALF.  Because we were interested in characterizing and 
exploring outcomes in the most acute cases of ALF, further analysis was restricted to ALF 
patients waitlisted Status-1 for LT.  Since Status-1 waitlisting requires strict criteria be met, 
this ensured that the cohort contained true ALF cases and was less likely to include acute on 
chronic liver failure patients or other misclassifications. Retransplant patients including some 
primary non-function cases were included in the primary analysis if they were waitlisted with 
a primary diagnosis of ALF and status-1. 
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Race or ethnicity was categorized as white, black, Hispanic, and Asian based on 
UNOS classification. Patients coded as American Indian, Alaskan Native, Hawaiian/Pacific 
Islander, multiracial, and other were excluded due to small sample size. UNOS provides a 
race/ethnicity category labeled ” ETHCAT” which classifies patients as white, black, 
Hispanic, or Asian, and also provides a category labeled  “ETHN”  which labels patients as 
non-Hispanic white or Hispanic/Latino. There were no patients labeled “ETHCAT” black but 
“ETHN” Hispanic. 
Clinical characteristics and demographics including age, gender, body mass index, 
history of diabetes, blood type, laboratory MELD score and its components at the time of 
waitlisting, grade of hepatic encephalopathy, ventilator status at time of waitlisting, the need 
for dialysis in the week prior to waitlisting, and region were compared between groups.  
Causative etiologies were divided into 7 categories including: 1) drug induced liver injury 
(DILI) secondary to acetaminophen, 2) DILI from other causes, 3) viral liver disease 
(hepatitis B virus, hepatitis A virus, hepatitis C virus, varicella zoster virus, herpes simplex 
virus), 4) autoimmune liver disease (AIH), 5) Wilsons Disease, 6) Other (including Budd 
Chiari, hepatic artery thrombosis, ischemic cholangiopathy, rejection, primary graft non-
function), and 7) unknown.  Causative etiologies were defined based primary and secondary 
diagnosis codes as well as free text diagnosis fields.   
The primary outcomes were LT and waitlist removal because of death or clinical 
deterioration.  Other removal was also explored and included removal because of being too 
well and removal for other reasons including UNOS code ‘other’.  These outcomes were 
identified using UNOS waitlist removal codes. The secondary outcome was 1-year post LT 
survival.   
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Statistical Analysis 
 
Baseline characteristics are presented as percentages, means for normally 
distributed variables, and medians for non-normally distributed variables. Chi-squared tests 
were used to compare categorical variables and rank sum and t-tests used to compare 
continuous variables.  
Absolute rates of LT were explored for the total cohort and by MELD quintile. Trends 
in waitlisting for Status-1 ALF patients were explored by comparing the percent change from 
2002 to 2016 and by using a Spearman test for trend to explore the trend over the entire 
study period by race and ethnicity. Competing risk analysis was used to compare risk of 
waitlist removal because of LT or death/clinical deterioration.  When differences in the 
primary outcome according to race/ethnicity were identified on univariable analysis, variables 
that were associated (p value <0.10) with the exposure and potentially associated with the 
outcome were added to the model to attempt to attenuate the disparity and explore the 
covariates contribution to the disparity. A full model that included all covariates was also 
explored. 
Kaplan Meier survival analysis was used to explore racial differences 1-year survival. 
Survival curves were compared using log rank testing.  All analyses were performed using 
STATA version 14 (STATA Corp, College Station, Texas). 
 
Results 
There were 151,317 adult patients who were black, white, Hispanic, or Asian 
waitlisted for LT during the study period.  Of the 8,408 patients waitlisted with a diagnoses of 
ALF, 4,501 patients were waitlisted Status-1 (55.3% of whites, 64.4% of blacks, 51.6% of 
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Hispanics, 40.7% of  Asians, p<0.001).  These 4,501 define the study cohort for the 
remainder of the analysis (Figure 1).  
The majority of patients with ALF waitlisted Status-1 were women, with the highest 
proportion of women in the black cohort (61.2% white, 70.2% black, 58.4% Hispanic, 52.0% 
Asian).  Black patients with ALF waitlisted Status-1 had higher MELD score (36 black vs 34 
white, 34 Hispanic, 35 Asian, p<0.001), INR (5.0 black vs 4.5 white, 4.3 Hispanic, 4.7 Asian, 
p=0.001), and bilirubin at waitlisting (17.9 mg/dl black vs 11.3 mg/dl white, 16.0 mg/dl 
Hispanic, and 16.7 mg/dl Asian, p<0.001) than other racial and ethnic groups (Table 1). 
There was no difference in the proportion of patients with grade 3 or 4 hepatic 
encephalopathy between the groups (Table 1). White patients were most likely to be on a 
ventilator at the time of waitlisting (Table 1).  There was no significant difference in the 
number of patients waitlisted for a retransplant for any cause among the four groups (3.4% 
white, 4.6% black, 2.7% Hispanic, 2.1% Asian, p=0.14).  
Trends in ALF over time 
The numbers of ALF patients waitlisted Status-1 has downtrended over the study 
period for all racial groups (Spearman: white -0.98, p<0.001; black -0.89, p<0.001, Hispanic -
0.78, p<0.001, Asian -0.76, p<0.001) (Figure 2) (Supplemental table 1).  Black patients 
continue to have the highest proportion of all registrants with ALF waitlisted Status-1 (white 
1.2%, Black 4.2%, Hispanic 1.7%, Asian 2.8%).  
Etiologies of ALF 
The etiology of ALF in patients waitlisted Status-1 was most often unknown in all 
racial/ethnic groups (Table 1). DILI secondary to acetaminophen was most common in white 
patients (27.0% white vs 10.5% black, 13.1% Hispanic, and 6.7% Asian, p<0.001). Black 
patients were significantly more likely to have AIH as the etiology of their ALF than other 
groups (9.4% blacks vs.  2.7% whites, 4.3% Hispanics, 2.7%, and Asian, p<0.001). ALF 
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secondary to viral etiologies was more common in Asian patients than other racial and ethnic 
groups (25.0% Asian vs 5.2% white, 10.6% black, and 8.4% Hispanic, p<0.001) (Table 1). 
 
Waitlist removal because of LT or death/clinical deterioration 
Of patients with ALF waitlisted Status-1 black patients were the most likely to be 
removed from the waitlist because of death or clinical deterioration (23.5% blacks vs 21.9% 
whites, 19.7% Hispanics, and 20.4% Asians; p<0.001).  The median MELD at removal was 
highest in black patients (41 blacks vs 38 whites, 38 Hispanics, 39 Asians) (Table 2).  The 
median time to death was 2 days for all racial and ethnic groups, with a interquartile range 
(IQR) between 0-4 days for all groups.  On competing risk analysis (competing risk: LT), 
however there was no significant difference in waitlist removal because of death or clinical 
deterioration between black and white patients (HR 1.04; 95% CI 0.89-1.21)(Table 3).   
Of patients with ALF waitlisted Status-1 black patients were the most likely to 
undergo LT (black 62.0%, vs 53.0% whites, 59.5% Hispanics, 59.8% Asians, p<0.001). The 
median MELD at LT was 35 for black patients and 34 for other racial and ethnic groups 
(p=0.06) (Table 2). The median time to LT was 2 days for all groups with an IQR between 1-
4 days for all groups. On competing risk analysis (competing risk: waitlist removal because 
of death or clinical deterioration) black patients were significantly more likely to undergo LT 
(HR 1.20; 95% CI 1.08-1.30) than white patients (Table 3). On multivariable analysis serum 
bilirubin (HR 1.04; 95% CI 0.94-1.14) as well as a full model which included age, BMI, blood 
type, gender, diabetes, bilirubin, INR, creatinine, causative etiology, grade 3-4 
encephalopathy, ventilator use, dialysis, and region explained the difference in LT (HR 1.00, 
95% CI 0.91-1.11) (Table 4).   
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We performed a separate analysis that excluded retransplant patients. There 
remained no racial/ethnic difference in waitlist removal because of death or clinical 
deterioration and black patients continued to be more likely than white patients to undergo 
LT. 
Eighty-nine percent of patients who were removed from the waitlist because of 
reasons other than LT or clinical deterioration/death were removed because of clinical 
improvement.  Black patients were the least likely to be removed from the waitlist for reasons 
other than death/clinical deterioration or LT (13.8% black, 24.8% white, 20.9% Hispanics, 
and 19.5% Asian, p<0.001) (Table 2).  
 
Post-transplant survival 
   Seventy-nine percent of the deaths that occurred (366/463) in the first year after LT 
occurred in the first 90 days.  While black patients had the lowest 90-day survival this 
difference was not significant (83.3% black vs 85.5% whites, 85.9% Hispanics, 91.4% 
Asians, p=0.09).  Black patients had significantly lower 1-year post transplant survival than 
other groups (79.6% blacks vs 82.8% whites, 83.9% Hispanics, 89.3% Asians, p=0.02) 
(Figure 3).   This remained true when retransplant patients were excluded from the analysis 
(78.0% blacks vs 81.6% whites, 83.1 % Hispanics, 88.9% in Asians, p=0.01).  
 
Discussion 
 ALF prognosis depends on the underlying causative etiology, age, duration of time 
over which the disease develops, the extent of the liver damage, and early institution of 
supportive care10 . It has not been clear how these prognostic factors vary by race or 
ethnicity. Here we demonstrate that the etiology of ALF in those adult patients that require 
Status-1 waitlisting varies by race and ethnicity.  We further demonstrate that black patients 
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waitlisted with ALF are sicker on presentation than other groups and are more often 
waitlisted Status-1.   This acuity lead to higher rates of LT in black patients compared to 
white patients, sparing black patients from higher rates of waitlist removal due to death or 
clinical deterioration. Black patients had the lowest 1-year post transplant survival in the 
cohort.  
The underlying cause of ALF is known to impact prognosis.  In a prospective study 
patients with acetaminophen overdose, hepatitis A, ischemic hepatitis, or pregnancy related 
ALF, survival without LT was greater than 50% compared to patient with ALF from 
indeterminate causes, non-acetaminophen overdose, hepatitis B virus, autoimmune 
hepatitis, Wilson disease, or Budd Chiari syndrome who had short-term transplant free 
survival of less than 25%11,12.    In our cohort, Hispanic and black patients were the most 
likely to have unknown causes of their ALF and black patients were also most to have AIH 
as a causative etiology.  It is possible that these underlying poor prognosis etiologies 
contributed to the higher rates of Status-1 waitlisting and LT for black patients. 
 In our study black patients had higher MELD scores, INR, and bilirubin on 
presentation than white patients.   Black patients with chronic liver disease have been shown 
to be sicker at waitlisting, with higher MELD scores than white patients8.   In a report from 
the ALF Study Group, black patients had similar MELD scores to white and Asian patients 
on presentation (blacks 33.9, whites 32.7, Asians 33.0; p=0.42), however they did have 
higher bilirubin than white patients (black 18.3 mg/dl vs 6.6 mg/dl whites)2. The higher 
bilirubin in black patients may reflect the differences in underlying causative etiology.  DILI, 
which is most often acetaminophen, presents with transaminitis while viral and unknown 
causes are more likely to have a component of cholestasis13 . The higher bilirubin and 
resultant higher MELD score likely drove the differences in Status-1 waitlisting and therefore 
LT between white and black patients.  
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 Black patients with ALF waitlisted Status-1 were more likely to undergo LT than 
white patients.   In the ALF Group database study, there was no difference in LT between 
black and white patients and higher rates of LT in Hispanic patients2.  In this cohort however 
not all patients were waitlisted for LT, therefore this likely represented a less critically ill 
population than our cohort. On multivariable analysis demographic, clinical, and allocation 
factors were able to fully explained (HR 1.20 HR 1.00) the difference in LT between black 
and whites, suggesting that these covariates contribute to the differences in LT between 
blacks in white patients waitlisted Status-1 for LT.   
It might have been expected that black patients would have higher rates of waitlist 
removal given their sicker presentation compared to white patients. However, the competing 
risk analysis suggest that LT was protective against waitlist removal.   White patients had the 
highest rates of other removal which is predominately removal for clinical improvement.   It is 
unclear if this is because of higher rates of acetaminophen DILI which has better prognosis, 
or reflects more aggressive evaluation and listing practices in this group.   
 Black patients with ALF waitlisted Status-1 for LT had lower 1-year post transplant 
survival than other groups while Asian patients had the highest 1-year post transplant 
survival.  Similar trends have been seen in chronic liver disease with lower 2-year and 5-year 
post transplant survival in black, patients14,15.  The reasons for these disparities are unclear. 
In chronic liver disease hypothesis include differences in recipient underlying health status, 
liver donor quality, and rejection16 .   
 This study is the first to explore causative etiologies and outcomes in a large cohort 
of black, Hispanic, and Asian patients with ALF waitlisted for LT.  This study has several 
potential limitations.  First, much of the data on causative etiologies depend on free text 
entered into the UNOS database. As such, patients in our cohort were classified as having 
an unknown cause of ALF at higher rates than prospective studies of ALF.    It is possible 
that there were misclassifications, however causative etiologies were unlikely to be coded 
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differently by race/ethnicity.  Second, we do not have explants histology or imaging to 
explore the potential hypothesis of acute on chronic liver disease in this cohort.  It is possible 
that black patients had a component of underlying chronic liver disease that lead to more 
acute presentation.  This potential bias lead us to focus on an ALF cohort that was waitlisted 
Status-1 therefore requiring the waitlisting physician to more thoroughly investigate the 
potential for underlying chronic liver disease. We included all patients with a diagnosis code 
of ALF and Status-1 waitlisting therefor some primary graft non-function patients and hepatic 
artery thrombosis patients were included.  However, when we excluded all re-transplants this 
did not change the univariable, multivariable, or post- transplant analysis. It is unclear why 
55% of registrants carried a diagnosis of ALF but were not waitlisted Status-1.  Again, this 
may have been due to acute on chronic liver failure, leading us to focus on those patients 
waitlisted Status-1 and most likely to have true ALF. Finally, we do not have information on 
the time from first identification of ALF and presentation to a LT center.   It is possible that 
delays in care lead to more severe liver disease on presentation in black patients compared 
to other racial groups and higher rates of LT. However it is notable that this was not seen in 
the Hispanic cohort who might be hypothesized to have similar issues with access to care.  
 In summary, this is the first study to explore prognostic factors including age, gender, 
causative disease etiology, as well as outcomes in a large cohort of diverse adult patients 
waitlisted for LT.  Causative etiologies of ALF in those patients waitlisted Status-1 vary by 
race and ethnicity. Furthermore, black patients are sicker on presentation and more 
frequently require LT for ALF.  Finally, black patients have lower 1-year post-transplant 
survival than other racial/ethnic groups.  Additional prospective studies are needed to 
determine if worse disease on presentation is related to late presentation or referral, acute 
on chronic liver disease, or inherently worse ALF. 
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Table 1. Clinical characteristics of adult patients with acute liver failure waitlisted status-1 for 
liver transplantation. 
 
   
White 
n=2,876 
Black 
n=790 
Hispanic 
n=513 
Asian 
n=328 
P value 
Age (years) 
(mean, SD) 
34.2± 9.4 36.3±9.0 34.4±9.0 34.8±9.0 <0.001 
Female  (%) 61.2% 70.2% 58.4% 52.0% <0.001 
BMI (mean, SD) 27.2 (6.1) 29.7 (7.4) 28.8  (6.4) 25.1 (4.6) <0.001 
Diabetes (%) 8.5% 9.1% 12.8% 11.0% 0.03 
Blood type O (%) 46.0% 50.6% 58.1 % 33.3 % <0.001 
Etiology of ALF     <0.001 
    
Acetaminophen 
27.0% 10.5% 13.1% 6.7%  
    DILI 6.8% 10.3% 9.2% 10.4%  
    Viral 5.3% 10.4% 8.4% 25.0%  
    AIH 2.7% 9.4% 4.3% 2.7%  
    Wilsons 0.6% 0.1% 1.0% 0.6%  
    Unknown 34.7% 42.8% 43.7% 37.8%  
MELD  
(median, IQ 
range) 
34 
(28-41) 
36 
(30-42) 
34 
(29-39) 
35 
(29-41) 
<0.001 
INR (mean, SD) 4.5 ± 4.3 5.0 ± 6.8 4.3± 3.7 4.7 ± 6.0 0.08 
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Creatinine (mg/dl) 
(mean, SD) 
2.1 ± 1.6 1.9 ± 1.6 1.8 ± 1.6 1.6 ± 1.5 <0.001 
Bilirubin (mg/dl)  
(mean, SD) 
11.3 ±10.5 17.9 ±11.1 16.0 ±11.4 16.7 ±11.3           <0.001 
Grade 3-4 HE (%) 60.0 63.2 58.7 55.5 0.09 
Ventilator (%) 53.5% 46.2% 49.7% 42.4% <0.001 
Dialysis (%) 12.8% 11.1% 13.1% 11.3% 0.75 
 
Abbreviations: Acute liver failure (ALF), model for end stage liver disease score (MELD), 
international normalized ration (INR), hepatic encephalopathy (HE). 
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Table 2. Waitlist removal in adult patients with acute liver failure waitlisted status-1 for liver 
transplantation, by race/ethnicity. 
  White 
n=2,876 
Black 
n=790 
Hispanic 
n=513 
Asian 
n=328 
P value 
Death or clinical 
deterioration 
630 
(21.9) 
186 
(23.5) 
101 
(19.7) 
67 
(20.4) 
<0.001 
Removal MELD 
(median, IQ range) 
38 
(31-44) 
41 
(13-75) 
38 
(31-44) 
39 
(31-46) 
0.01 
Transplanted 1,524 
(53.0) 
490 
(62.0) 
305 
(59.5) 
196 
(59.8) 
<0.001 
Transplant MELD 
(median, IQ range) 
34 
(27-40) 
35 
(30-40) 
34 
(28-39) 
34 
(28-41) 
0.06 
Other removal* 713 
(24.8) 
114 
(13.8) 
107 
(20.9) 
64 
(19.5) 
<0.001 
Remained on 
waitlist 
9 
(0.5) 
0 
(0) 
0 
(0) 
1 
(0.3) 
0.25 
 
Abbreviations: model for end stage liver disease score (MELD) 
*Eighty-nine percent of other removals were defined as being removed because of clinical 
improvement.  
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Table 3. Competing risk analysis: liver transplantation and waitlist removal because of death 
or clinical deterioration, by race/ethnicity 
  Unadjusted HR 
(95% CI) 
Death or Clinical Deterioration  
White Reference 
          Black HR 1.04 ( CI 0.89-1.21) 
          Hispanic HR 0.87 (0.71-1.08) 
          Asian HR 0.88 (0.69-1.13) 
Transplanted  
White Reference 
          Black HR 1.20  (CI 1.08-1.30) 
          Hispanic HR  1.11 (1.00-1.25) 
          Asian HR 1.13 (0.98-1.3) 
Abbreviations: Hazard ration (HR) 
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Table 4.  Competing risk multivariable analysis:  liver transplantation in black compared to 
white adult patients 
 HR (95% CI) 
Unadjusted  1.20 (1.081.30) 
 
Adjusted for single variable  
Age 1.20 (1.09-1.32) 
BMI 1.15 (1.04-1.27) 
Diabetes 1.20 (1.09-1.32) 
Blood type 1.20 (1.10-1.33) 
Gender 1.19 (1.09-1.32) 
Bilirubin 1.04 (0.94-1.14) 
 
INR 1.19 (1.08-1.30) 
 
Creatinine 1.18 (1.07-1.30) 
 
MELD 1.18 (1.08-1.30) 
Etiology 1.09 (1.00-1.20) 
 
Grade 3-4 HE 1.19 (1.09-1.31) 
Ventilator  1.18 (1.08-1.30) 
Dialysis 1.19 (1.08-1.30) 
Region 1.14 (1.04-1.25) 
Full model*  
 1.00 (0.91-1.11) 
 
Abbreviations: Hazard ration (HR), model for end stage liver disease score (MELD), 
international normalized ration (INR) 
*includes all variables in table except MELD. Variables are categorized as presented in 
Table 1 
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Figure 1. Consort Diagram: Adult patients waitlisted for liver transplantation with acute liver 
failure and ultimately waitlisted status-1 
A. All patient waitlisted for LT and the denominator of Figure 2 B. Patients with diagnosis 
code for ALF C Patients with a diagnosis code for ALF and waitlisted Status-1, the 
numerator for Figure 2, and they study cohort 
 
Figure 2.  Trends in acute liver failure in adult patients waitlisted status 1 from 2002-2016 in 
patients by race/ethnicity.  
Abbreviations: Acute Liver Failure (ALF) 
 
Figure 3.  Kaplan-Meier 1-year post liver transplant survival 
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